Information Provided By:
Fly News Breaks for August 26, 2019
SGEN
Aug 26, 2019 | 07:30 EDT
BTIG analyst Thomas Shrader initiated Seattle Genetics with a Neutral rating. The analyst is positive on the company's antibody drug conjugate, or ADC, leadership and its efforts to broaden that label in Hodgkin lymphoma, but warns that its next growth leg for the new generation of ADCs will involve in diseases that are "much tougher" to treat and come against greater competition. Shrader also believes that much of the good news for Seattle Genetics has been priced into the stock.
News For SGEN From the Last 2 Days
There are no results for your query SGEN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.